RT Journal Article SR Electronic T1 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 170057 DO 10.1183/16000617.0057-2017 VO 26 IS 146 A1 Lisa H. Lancaster A1 Joao A. de Andrade A1 Joseph D. Zibrak A1 Maria L. Padilla A1 Carlo Albera A1 Steven D. Nathan A1 Marlies S. Wijsenbeek A1 John L. Stauffer A1 Klaus-Uwe Kirchgaessler A1 Ulrich Costabel YR 2017 UL http://err.ersjournals.com/content/26/146/170057.abstract AB Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival. Long-term extension trials, registries and real-world studies have also shown similar treatment effects with pirfenidone. However, for patients with IPF to obtain the maximum benefits of pirfenidone treatment, the potential adverse events (AEs) associated with pirfenidone need to be managed. This review highlights the well-known and established safety profile of pirfenidone based on randomised controlled clinical trials and real-world data. Key strategies for preventing and managing the most common pirfenidone-related AEs are described, with the goal of maximising adherence to pirfenidone with minimal AEs.Using key strategies to prevent and manage pirfenidone-related AEs can help maximise adherence to pirfenidone http://ow.ly/Veyk30gsFTs